ALPMY News and Press, Astellas Pharma Inc. ADR From 04/11/23

CiRA, Kyoto University and Astellas Second Phase Joint Research Agreement Signed for Medical Applications of iPS Cells PR Newswire KYOTO, Japan and TOKYO , April 11, 2023 /PRNewswire/ -- The Center for iPS Cell Research and Application, Kyoto University (...

2023-04-04 08:35:08 ET Summary Its lead drug candidate is in Phase 3 development for multiple leukemia indications. Mechanism has utility in other cancer and non-cancer diseases. Perceived trial delays punished the stock. Delays actually raise the odds of greater survival ...

FDA Grants Accelerated Approval for PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Locally Advanced or Metastatic Urothelial Cancer PR Newswire – First treatment option combining an antibody-drug conjugate plus a...

2023-04-01 16:00:21 ET Pfizer's ( NYSE: PFE ) acquisition of Seagen ( NASDAQ: SGEN ), announced in March, is expected to complement the pharma giant's current portfolio of oncology therapies. Seagen focuses on antibody-drug conjugates (ADCs), a technology that the co...

2023-03-29 04:41:23 ET Astellas Pharma ( OTCPK:ALPMF ) ( OTCPK:ALPMY ) is collaborating with Roche Diabetes Care Japan to develop and commercialize Roche's Accu-Chek Guide Me blood glucose monitoring system as a combined product with an app called BlueStar. Astellas s...

Astellas and Roche Diabetes Care Japan ink partnership agreement to develop and commercialize integrated diabetes self-management solution with BlueStar® PR Newswire - Accu-Chek ® Guide Me glucose meter to be paired with BlueStar ® in Japan ,...

Astellas Announces Positive Findings from Phase 3 GLOW Trial of Zolbetuximab during March ASCO Plenary Series PR Newswire Data shows investigational zolbetuximab plus CAPOX reduced risk of progression or death by 31.3% vs CAPOX alone Study evaluated patients with Claud...

Phase 3 Study Shows XTANDI® (enzalutamide) plus Leuprolide Significantly Improves Metastasis-Free Survival in Men with Non-Metastatic Prostate Cancer PR Newswire Pfizer and Astellas announce positive topline results from Phase 3 EMBARK trial NEW YORK and TOK...

2023-03-15 09:10:29 ET The Biden administration on Wednesday published a list of 27 Medicare Part B drugs that will be subject to inflation penalties for the first time in the U.S., including some key pipeline products from AbbVie ( ABBV ), Gilead ( GILD ), and Seagen ( SGEN ...

Results from Astellas' Pivotal Phase 3 SKYLIGHT 1™ Study of Fezolinetant for Vasomotor Symptoms Due to Menopause Published in The Lancet PR Newswire Treatment with fezolinetant resulted in statistically significant reductions in the frequency and severity of VMS and imp...